JP Morgan Downgrades Dow to Neutral
JP Morgan analyst Jeffrey Zekauskas downgrades Dow (NYSE:DOW) from Overweight to Neutral.
Jefferies Downgrades Forma Therapeutics Hldgs to Hold, Lowers Price Target to $20
Jefferies analyst Maury Raycroft downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Buy to Hold and lowers the price target from $28 to $20.
Okta Stock Is Sliding Down, Despite 6 Analysts’ Mixed Takes on Q2 Earnings, Guidance
Shares of Okta Inc (NASDAQ: OKTA) fell in after-hours trading, despite the company reporting a lower-than-expected loss for the second quarter.
JMP Securities On Okta
Cloud Customer Behavior And Asian ‘Economic Trends’ Prompts Analyst ‘Concern’ About Memory Stocks
Benchmark analyst Mark Miller downgraded Western Digital Corp (NASDAQ: WDC)
Credit Suisse Downgrades VNET Gr to Neutral, Lowers Price Target to $5.9
Credit Suisse analyst Clive Cheung downgrades VNET Gr (NASDAQ:VNET) from Outperform to Neutral and lowers the price target from $7.2 to $5.9.
Loop Capital Downgrades HP to Hold, Lowers Price Target to $29
Loop Capital analyst Ananda Baruah downgrades HP (NYSE:HPQ) from Buy to Hold and lowers the price target from $50 to $29.
Morgan Stanley Downgrades Okta to Equal-Weight, Announces $93 Price Target
Morgan Stanley analyst Hamza Fodderwala downgrades Okta (NASDAQ:OKTA) from Overweight to Equal-Weight and announces $93 price target.
Needham Downgrades Okta to Hold
Needham analyst Alex Henderson downgrades Okta (NASDAQ:OKTA) from Buy to Hold.
Bryan Garnier Downgrades Molson Coors Beverage to Sell, Announces $54 Price Target
Bryan Garnier analyst Nikolaas Faes downgrades Molson Coors Beverage (NYSE:TAP) from Buy to Sell and announces $54 price target.
Canaccord Genuity Downgrades Okta to Hold, Lowers Price Target to $85
Canaccord Genuity analyst Michael Walkley downgrades Okta (NASDAQ:OKTA) from Buy to Hold and lowers the price target from $155 to $85.